highly significantp < 0.001
Hemorrhagic manifestations were significantly more prevalent among confirmed cases, particularly injection site bleeding (68%), ocular bleeding (80%), and subcutaneous bleeding (84%) in 2022, with all differences being highly significant ( p < 0.001).